Ozanimod for treating relapsing–remitting multiple sclerosis – guidance (TA706)

NICE do not recommend ozanimod for relapsing–remitting multiple sclerosis in adults. Trial evidence shows ozanimod reduces relapses vs interferon beta-1a, but the cost effectiveness estimates were higher than what is normally considered an acceptable use of NHS resources.

Source:

National Institute for Health and Care Excellence